Publicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (12)

2021

  1. The APOB polymorphism rs1801701 A/G (p.R3638Q) is an independent risk factor for early-onset coronary artery disease: Data from a Spanish cohort

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 31, Núm. 5, pp. 1564-1568

  2. Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity

    International Immunopharmacology, Vol. 98

2018

  1. Genetic Variation in the H19-IGF2 Cluster Might Confer Risk of Developing Impaired Renal Function

    DNA and Cell Biology, Vol. 37, Núm. 7, pp. 617-625

2017

  1. Screening of the Filamin C Gene in a Large Cohort of Hypertrophic Cardiomyopathy Patients

    Circulation: Cardiovascular Genetics, Vol. 10, Núm. 2

2015

  1. Next generation sequencing search for uromodulin gene variants related with impaired renal function

    Molecular Biology Reports, Vol. 42, Núm. 9, pp. 1353-1358

2014

  1. Effect of the FTO rs9930506 Polymorphism on the Main Comorbidities of the Cardiorenal Metabolic Syndrome in an Elderly Spanish Cohort

    CardioRenal Medicine, Vol. 4, Núm. 2, pp. 82-87

2013

  1. A common APOE polymorphism is an independent risk factor for reduced glomerular filtration rate in the Spanish RENASTUR cohort

    CardioRenal Medicine, Vol. 3, Núm. 2, pp. 113-119

2010

  1. Cistatina C y riesgo cardiovascular en población general

    Revista Espanola de Cardiologia, Vol. 63, Núm. 4, pp. 415-422

2006

  1. Prevalence of abnormal urinary albumin excretion rate in hypertensive patients with impaired fasting glucose and its association with cardiovascular disease

    Journal of the American Society of Nephrology

  2. Urinary albumin excretion and glomerular filtration rate across the spectrum of glucose abnormalities in essential hypertension

    Journal of the American Society of Nephrology

2005

  1. Prevalencia de insuficiencia renal «oculta» en población diabética tipo 2

    Atencion Primaria, Vol. 35, Núm. 7, pp. 359-364

2003

  1. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine

    European Neurology, Vol. 49, Núm. 1, pp. 20-29